TCL Archive In Brief: Oldham To Head Biological Response Modifiers Program; Walter, Namovicz Named Acting Heads August 8, 1980
TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive In Brief: Calabresi Named To President’s Cancer Panel; Mays Leaves NCI Technology Office For IVAX May 5, 1995
TCL Archive In Brief: Curran Moves From Fox Chase To Jefferson; Groundbreaking From UNC Lineberger Center December 2, 1994
